Probiotic Therapy in Patients with Nonalcoholic Steatohepatitis in Zagazig University Hospitals.
Probiotic Therapy in Patients with Nonalcoholic Steatohepatitis in Zagazig University Hospitals.
复制标题
DOI：
10.5005/jp-journals-10018-1226
复制
发表时间：
2017-01
期刊：
影响因子：
--
通讯作者：
Abdel Monem SM
中科院分区：
文献类型：
--
作者：
Abdel Monem SM
非酒精性脂肪性肝病（NAFLD）可能是世界上最常见的肝脏疾病。NAFLD患者的亚组的特征在于除了过量脂肪之外的肝细胞损伤和炎症（脂肪性肝炎），后一种病症被命名为非酒精性脂肪性肝炎（NASH）。这项工作旨在评估益生菌对扎加齐格大学医学院热带医学系收治的患者（住院患者和门诊患者）NASH结局的作用。本研究对30名患者（17名男性和13名女性）进行，体重指数为30至35，平均年龄为44岁，超声检查显示明亮的脂肪肝，丙氨酸转氨酶（ALT）和天冬氨酸转氨酶（AST）升高，肝活检结果阳性。患者被分为第一组（病例组），包括15名接受益生菌治疗的患者，第二组15名未接受益生菌治疗的患者作为对照组;研究于2014年11月至2016年4月进行。所有病例均进行临床评估、实验室评估、盆腔-腹部超声检查和肝活检。在本研究中，肝酶（ALT和AST）显着下降，其他实验室检查结果无统计学意义。一些患者的消化不良也得到缓解。益生菌治疗是有效的，安全的，耐受性良好的，廉价的，适合长期使用，并且最佳地，在多个水平上下调炎症介质，因此，益生菌可能是NASH治疗的一种选择。如何引用这篇文章：Monem SMA。Zagazig大学医院非酒精性脂肪性肝炎患者的益生菌治疗。欧亚肝胃肠道杂志2017;7（1）：101-106。
Nonalcoholic fatty liver disease (NAFLD) is probably the most common liver disorder in the world. A subgroup of NAFLD patients is characterized by injury to the hepatocytes and inflammation in addition to excessive fat (steatohepatitis), the latter condition is nominated nonalcoholic steatohepatitis (NASH). This work aimed to evaluate the role of probiotics on the outcome of NASH in patients admitted to the Tropical Medicine Department, Faculty of Medicine, Zagazig University (inpatients and outpatients). This study was performed on 30 patients (17 males and 13 females), with body mass index from 30 to 35 and average age of 44 years with bright fatty liver in ultrasonography and raised alanine transaminase (ALT) and aspartate transaminase (AST) and positive liver biopsy findings. The patients were divided into group I (case group) that included 15 patients who received probiotics and group II of 15 patients as control group who did not receive probiotics; the study was conducted between November 2014 and April 2016. Clinical assessment, laboratory evaluation, pelvic-abdominal ultrasound, and liver biopsy of all cases were carried out. In this study, there was significant decrease in liver enzymes (ALT and AST) and no statistically significant other laboratory findings. Also there was relief for dyspepsia in some patients. Probiotics treatment is effective, safe, well-tolerated, inexpensive, appropriate for long-term use, and optimally, works at multiple levels to downregulate inflammatory mediators, and therefore, probiotics could be an option in the treatment of NASH. How to cite this article: Monem SMA. Probiotic Therapy in Patients with Nonalcoholic Steatohepatitis in Zagazig University Hospitals. Euroasian J Hepato-Gastroenterol 2017;7(1):101-106.